Variantside

Variantside is a genetics company that specializes in the development and commercialization of next-generation sequencing (NGS) tests and analytics for the detection and identification of genetic variants associated with various diseases.

The company's core technology is based on a multiplexed targeted sequencing approach, which enables the simultaneous analysis of multiple genes and genetic variations in a single reaction. This allows for a high degree of resolution and sensitivity in the detection of genetic variants, including point mutations, insertions, deletions, and copy number variations.

Variantside's NGS tests and analytics are primarily aimed at the diagnostic and research communities, with a focus on the detection of genetic variants associated with rare diseases, cancer, and other complex diseases. The company's technology is also applicable to the identification of somatic genetic variants in tumor samples, which can aid in the development of personalized cancer therapies.

Some of the key benefits of Variantside's technology include improved variant detection sensitivity and specificity, as well as the ability to detect and analyze large numbers of genes and genetic variants in a single experiment. This enables researchers and clinicians to gain a more comprehensive understanding of the genetic underpinnings of complex diseases.

Variantside has received recognition and funding for its innovative approach to genomics and its potential to improve human health. However, as with any genetic testing company, regulatory approval and compliance are essential aspects of its business operations, ensuring the safe and responsible use of its technology.